Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin

BusinessWire_EN 
0 0 17.12.20
Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin: https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
 

MedinCell (Paris:MEDCL):

Study’s first results presented at the international “Collaborative Workshop – Ivermectin against Covid-19” held on December 15, 16 and 17 at the initiative of MedinCell.

No side effects observed with the first two doses in the study, which includes a total of three doses.

A first long-acting injectable formulation is ready to enter regulatory development.

Access the complete press release.

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006045/en/

Medincell S.a. Stock

€14.84
-0.270%
Medincell S.a. shows a slight decrease today, losing -€0.040 (-0.270%) compared to yesterday.

Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!